LOS ANGELES--(BUSINESS WIRE)--Dec. 15, 2005--BiomedDiscoveries.com --
http://www.BiomedDiscoveries.com, the online source for exclusive
investor information in the biotechnology sector, today announced the
online availability of a new Q&A style interview with Dr. Dov Shimon,
Chief Medical Officer and Director of MIV Therapeutics (OTCBB:
MIVT -
News; FWB:MIV), a leading developer of new generation biocompatible
coatings and advanced drug delivery systems.
In the interview, Dr. Shimon provides details of results from a
pivotal long-term animal study of MIVT's proprietary Ultra-thin
Hydroxyapatite (HAp) coating. In the recently completed study, a
coronary stent coated with MIVT's HAp formulation was implanted in a
porcine coronary artery. The coating was then studied over a six-month
period to examine its biocompatibility, safety and efficacy in the
animal's body.
The results showed the HAp coating to have, "superb compatibility
and zero reactivity," Dr. Shimon said. "A number of variables were
looked at in the study -- the exact measure of narrowing inside the
stent reaction, beyond the stent, etc. -- and we're happy to report
that there have been no adverse effects or reactions to the coating
material."
He continued, "There are over one million patients every year who
undergo implantation of coronary stents in the United States alone, to
give an idea of how many patients' lives could be affected and
improved by MIV Therapeutics' leadership in optimizing stent coating
safety."
The study was performed at the Center for Research in
Cardiovascular Interventions of the Methodist Hospital Research
Institute, an independent research organization that is highly
distinguished in the field.
Stents are coil-like metal devices that are used to prop open
blocked arteries in cardiac patients. The results are expected to help
pave the way to upcoming clinical trials with humans volunteers, and
ultimately, to the Company's planned commercialization of this
possible breakthrough technology in the fast-growing,
multi-billion-dollar global stent marketplace.
MIVT has developed a portfolio of patented HAp coating
technologies based on an organic substance found in human bone and
teeth, in order to eliminate serious risks that are often associated
with today's generation of polymer-based coatings on the market. The
Q&A interview can be read free of charge by visiting
http://www.BiomedDiscoveries.com.
About MIV Therapeutics, Inc.
MIV Therapeutics, Inc. is developing a next-generation line of
advanced biocompatible coatings for passive and drug-eluting
application on cardiovascular stents and for application on a broad
range of other implantable medical devices. The Company's ultra-thin
coating formulation is designed primarily to protect surrounding
tissue from the chemical interaction with metal stents. The Company's
unique ultra-thin coating has been derived from a biocompatible
material called Hydroxyapatite (HAp) that during in-vivo animal trials
demonstrated excellent safety and exceptional biocompatibility pursued
by the science in the field of advanced implantable drug delivery
systems. Hydroxyapatite is a bioactive porous material that makes up
the bone mineral and matrix of teeth. It is widely used as a bone
substitute material and for coating implantable fixation devices in
orthopedic, dental and other applications. The Company's novel
drug-eluting technologies based on Hydroxyapatite provide an
attractive alternative solution to polymer-based drug-eluting coatings
currently in the stent market. The Company's drug-eluting coating is
designed to suit a broad range of implantable medical devices which
may benefit from a highly customizable drug release profile. MIVT
reached a Collaborative Research Agreement (CRA) with the University
of British Columbia and supported a research and development grant
from the Natural Sciences and Engineering Research Council of Canada
(NSERC) in 2002 for the development of Hydroxyapatite as a
drug-eluting coating. In December 2004 MIVT received a Government
grant for the research program titled "Development of Novel Drug
Eluting Composite Coatings for Cardiovascular Stents" under the
National Research Council -- Industrial Research Assistance Program
(NRC-IRAP). Under this sponsorship the Company will progress to the
development stage, which is expected to finalize the drug-eluting
research and development Program. For more information, please visit
http://www.trilogy-capital.com/tcp/mivt/website.html. To read or
download MIV Therapeutics' Investor Fact Sheet, visit
http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain
daily and historical Company stock quote data, and recent Company news
releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT
is traded on the Frankfurt, Germany, stock exchange under the symbol
MIV.
About BiomedDiscoveries.com
BiomedDiscoveries.com provides exclusive commentary, research,
interviews and other information about the smallcap investment
marketplace. BiomedDiscoveries.com strives to provide investors with
information and research-based data regarding important individual
companies and overall marketplace trends. Resources available on
BiomedDiscoveries.com include audio interviews with corporate leaders
and respected commentators, as well as technical white papers and
other forms of market and investment analysis. It is located at
http://www.BiomedDiscoveries.com.
Forward-Looking Statements
Except for the historical information contained herein, the
matters discussed in this press release are forward-looking
statements. Such statements are indicated by words or phrases such as
"believe," "will," "breakthrough," "significant," "indicated," "feel,"
"revolutionary," "should," "ideal," "extremely" and "excited." These
statements are made under "Safe Harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Actual results may differ
materially from those described in forward-looking statements and are
subject to risks and uncertainties. See the Company's filings with the
Securities and Exchange Commission including, without limitation, the
Company's recent Form 10-K and Form 10-Qs, which identify specific
factors that may cause actual results or events to differ materially
from those described in the forward-looking statements.
Compensation and Other Disclosures
BiomedDiscoveries.com is a wholly owned subsidiary of Trilogy
Capital Partners, Inc. Trilogy Capital Partners provides investor
relations services to public companies. The companies presented by
BiomedDiscoveries.com are usually clients of Trilogy Capital Partners
and compensate Trilogy Capital Partners for these services, including
cash compensation and equity securities. In addition, Trilogy Capital
Partners and its affiliates may own securities of the presenting
companies, and may from time to time purchase and sell securities of
these companies in the open market or in private transactions. Trilogy
receives compensation from MIV Therapeutics of $10,000 per month
through November 2005 and thereafter for so long as Trilogy is
retained to provide investor relations services. Trilogy has
non-transferable warrants from this company to purchase 2,720,000
shares of common stock for $0.26 per share and expiring in November
2007, provided that Trilogy may not exercise the warrants to the
extent that following such exercise Trilogy would beneficially own 5%
or more or the outstanding common stock of this company.
